Press Release Details

Cerus and the Community Blood Center of the Carolinas Enter into Agreement for the Use of INTERCEPT Platelets and Plasma

October, 06 2015

CONCORD, Calif. & CHARLOTTE, N.C.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that the Community Blood Center of the Carolinas (CBCC) has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. CBCC provides over 12,000 platelet and 22,000 plasma units annually to 27 regional hospitals.

“Our goal is to provide blood components of the highest possible level of quality and safety for the hospitals and patients we serve," said Martin Grable, CBCC's president and chief executive officer. “INTERCEPT-treated platelets and plasma enable us to offer an even safer choice of blood components in the Carolinas.”

“We are proud to work with CBCC to bring pathogen-reduced platelets and plasma to the Carolinas. We believe everyone should have access to pathogen-reduced platelets and plasma and CBCC’s goal of providing blood components with the highest quality and safety standards is consistent with Cerus' own mission,” commented William 'Obi' Greenman, Cerus’ president and chief executive officer.


The Community Blood Center of the Carolinas (CBCC) is a non-profit community-based blood center and the primary blood supplier to 27 regional hospitals, serving 19 North Carolina and three South Carolina counties. It focuses exclusively on gathering red blood cells, platelets and plasma from volunteer donors to save local lives in the Carolinas. CBCC is a member of America’s Blood Centers, North America’s largest network of community-based, independent blood centers, providing more than 50% of the nation’s blood supply. For more information, visit


Cerus Corporation is a biomedical products company focused in the field of blood safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Source: Cerus Corporation

Cerus Investor Relations Contacts:

Stacey Leanos, 925-288-6137

Associate Director, Investor & Public Relations


Lainie Corten, 925-288-6137

Vice President, Global Marketing & Investor Relations


Cerus Media Contact:

ARC2 Communications & Media, Inc.

Dan Boyle, 818-209-1692


Community Blood Center of the Carolinas

Martin Grable, CEO, 704-972-4703

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600